Centre for Policy on Ageing



Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended)
Corporate Author	National Institute for Health and Clinical Excellence - NICE
Publisher	National Institute for Health and Clinical Excellence - NICE, London, September 2007
Pages	4 pp (NICE technology appraisal guidance 111 (amended))
Source	NICE, MidCity Place, 71 High Holborn London WC1V 6NA. http://www.nice.org.uk
Keywords	Dementia ; Drugs ; Standards of provision.
Annotation	Following the outcome of a judicial review in August 2007, NICE has amended and reissued this guidance which was originally issued in November 2006. This guidance constitutes a review of 'NICE technology appraisal guidance 19' on the use of donepezil, galantamine and rivastigmine for the treatment of mild to moderately severe Alzheimer's disease (AD), published in 2001, and a new appraisal of the clinical and cost effectiveness of memantine for moderately severe to severe Alzheimer's disease. For the NICE guidance, quick reference guide, lay version and other information, see http://www.nice.org.uk/TA111, which states that this current guidance is expected to be reviewed in September 2009 (KJ/RH).
Accession Number	CPA-070928201 P
Classmark	EA: LLD: 583 *
Data © Centre for Policy on Ageing

...from the Ageinfo database published by Centre for Policy on Ageing.